BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 15252314)

  • 1. Apo D in soft tissue tumors: a novel marker for dermatofibrosarcoma protuberans.
    West RB; Harvell J; Linn SC; Liu CL; Prapong W; Hernandez-Boussard T; Montgomery K; Nielsen TO; Rubin BP; Patel R; Goldblum JR; Brown PO; van de Rijn M
    Am J Surg Pathol; 2004 Aug; 28(8):1063-9. PubMed ID: 15252314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apolipoprotein D in CD34-positive and CD34-negative cutaneous neoplasms: a useful marker in differentiating superficial acral fibromyxoma from dermatofibrosarcoma protuberans.
    Lisovsky M; Hoang MP; Dresser KA; Kapur P; Bhawan J; Mahalingam M
    Mod Pathol; 2008 Jan; 21(1):31-8. PubMed ID: 17885669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential expression of HMGA1 and HMGA2 in dermatofibroma and dermatofibrosarcoma protuberans: potential diagnostic applications, and comparison with histologic findings, CD34, and factor XIIIa immunoreactivity.
    Li N; McNiff J; Hui P; Manfioletti G; Tallini G
    Am J Dermatopathol; 2004 Aug; 26(4):267-72. PubMed ID: 15249855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurofibromatous changes in dermatofibrosarcoma protuberans: a potential pitfall in the diagnosis of a serious cutaneous soft tissue neoplasm.
    Kovarik CL; Hsu MY; Cockerell CJ
    J Cutan Pathol; 2004 Aug; 31(7):492-6. PubMed ID: 15239679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stromelysin-3 expression in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans: comparison with factor XIIIa and CD34.
    Kim HJ; Lee JY; Kim SH; Seo YJ; Lee JH; Park JK; Kim MH; Cinn YW; Cho KH; Yoon TY
    Br J Dermatol; 2007 Aug; 157(2):319-24. PubMed ID: 17596171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrosarcomatous ("high-grade") dermatofibrosarcoma protuberans: clinicopathologic and immunohistochemical study of a series of 41 cases with emphasis on prognostic significance.
    Mentzel T; Beham A; Katenkamp D; Dei Tos AP; Fletcher CD
    Am J Surg Pathol; 1998 May; 22(5):576-87. PubMed ID: 9591728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dermatofibrosarcoma: a rare form of soft tissue. Management and review of the literature.
    Kontzoglou K; Stamatakos M; Polyzou E; Levidou G; Iannescu R; Safioleas M
    Chirurgia (Bucur); 2011; 106(5):653-6. PubMed ID: 22165066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-affinity nerve growth factor receptor (p75) in dermatofibrosarcoma protuberans and other nonneural tumors: a study of 1,150 tumors and fetal and adult normal tissues.
    Fanburg-Smith JC; Miettinen M
    Hum Pathol; 2001 Sep; 32(9):976-83. PubMed ID: 11567228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of CD34 and D2-40 in the Differentiation of Dermatofibroma and Dermatofibrosarcoma Protuberans.
    Sadullahoğlu C; Dere Y; Atasever TR; Öztop MT; Karaaslan Ö
    Turk Patoloji Derg; 2017; 1(1):223-227. PubMed ID: 28832078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A study of CD117 expression in dermatofibrosarcoma protuberans and cellular dermatofibroma.
    Labonte S; Hanna W; Bandarchi-Chamkhaleh B
    J Cutan Pathol; 2007 Nov; 34(11):857-60. PubMed ID: 17944726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of bcl-2 oncoprotein in benign and malignant spindle cell tumors of soft tissue, skin, serosal surfaces, and gastrointestinal tract.
    Suster S; Fisher C; Moran CA
    Am J Surg Pathol; 1998 Jul; 22(7):863-72. PubMed ID: 9669348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical characterization of dermatofibrosarcoma protuberans with practical applications for diagnosis and treatment.
    Haycox CL; Odland PB; Olbricht SM; Piepkorn M
    J Am Acad Dermatol; 1997 Sep; 37(3 Pt 1):438-44. PubMed ID: 9308560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of CD163 in dermatofibroma, cellular fibrous histiocytoma, and dermatofibrosarcoma protuberans: comparison with CD68, CD34, and Factor XIIIa.
    Sachdev R; Sundram U
    J Cutan Pathol; 2006 May; 33(5):353-60. PubMed ID: 16640542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sclerosing Dermatofibrosarcoma Protuberans Shows Significant Overlap With Sclerotic Fibroma in Both Routine and Immunohistochemical Analysis: A Potential Diagnostic Pitfall.
    Abdaljaleel MY; North JP
    Am J Dermatopathol; 2017 Feb; 39(2):83-88. PubMed ID: 28134725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IGFBP7, a novel immunohistochemical marker in differentiating dermatofibroma from dermatofibrosarcoma protuberans.
    Li J; Yu Y; Yang Y; Wang L; Cao J; Liang X; Xiao X; Tu Y; Chen H
    J Eur Acad Dermatol Venereol; 2012 Mar; 26(3):382-5. PubMed ID: 21492256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD34 and factor-XIIIa immunoreactivity in dermatofibrosarcoma protuberans and dermatofibroma.
    Goldblum JR; Tuthill RJ
    Am J Dermatopathol; 1997 Apr; 19(2):147-53. PubMed ID: 9129699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dermatofibrosarcoma protuberans, giant cell fibroblastoma, and hybrid lesions in children: clinicopathologic comparative analysis of 28 cases with molecular data--a study from the French Federation of Cancer Centers Sarcoma Group.
    Terrier-Lacombe MJ; Guillou L; Maire G; Terrier P; Vince DR; de Saint Aubain Somerhausen N; Collin F; Pedeutour F; Coindre JM
    Am J Surg Pathol; 2003 Jan; 27(1):27-39. PubMed ID: 12502925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical analysis of platelet-derived growth factor and its receptors in fibrohistiocytic tumors.
    Taniuchi K; Yamada Y; Nonomura A; Takehara K
    J Cutan Pathol; 1997 Aug; 24(7):393-7. PubMed ID: 9274955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tenascin differentiates dermatofibroma from dermatofibrosarcoma protuberans: comparison with CD34 and factor XIIIa.
    Kahn HJ; Fekete E; From L
    Hum Pathol; 2001 Jan; 32(1):50-6. PubMed ID: 11172295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LN-2 (CD74). A marker to distinguish atypical fibroxanthoma from malignant fibrous histiocytoma.
    Lazova R; Moynes R; May D; Scott G
    Cancer; 1997 Jun; 79(11):2115-24. PubMed ID: 9179057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.